title: Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application.
abstract: Proteomics studies typically aim to exhaustively detect peptides/proteins in a given biological sample. Over the past decade, the number of publications using proteomics methodologies has exploded. This was made possible due to the availability of high-quality genomic data and many technological advances in the fields of microfluidics and mass spectrometry. Proteomics in biomedical research was initially used in 'functional' studies for the identification of proteins involved in pathophysiological processes, complexes and networks. Improved sensitivity of instrumentation facilitated the analysis of even more complex sample types, including human biological fluids. It is at that point the field of clinical proteomics was born, and its fundamental aim was the discovery and (ideally) validation of biomarkers for the diagnosis, prognosis, or therapeutic monitoring of disease. Eventually, it was recognized that the technologies used in clinical proteomics studies [particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS)] could represent an alternative to classical immunochemical assays. Prior to deploying MS in the measurement of peptides/proteins in the clinical laboratory, it seems likely that traditional proteomics workflows and data management systems will need to adapt to the clinical environment and meet in vitro diagnostic (IVD) regulatory constraints. This defines a new field, as reviewed in this article, that we have termed quantitative Clinical Chemistry Proteomics (qCCP).
authors.affiliation: CHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, and Université Montpellier 1, and INSERM U1040, Montpellier, France. s-lehmann@chu-montpellier.fr
authors.forename: Sylvain
authors.initials: S
authors.lastname: Lehmann
authors.forename: Andrew
authors.initials: A
authors.lastname: Hoofnagle
authors.forename: Denis
authors.initials: D
authors.lastname: Hochstrasser
authors.forename: Cato
authors.initials: C
authors.lastname: Brede
authors.forename: Matthias
authors.initials: M
authors.lastname: Glueckmann
authors.forename: José A
authors.initials: JA
authors.lastname: Cocho
authors.forename: Uta
authors.initials: U
authors.lastname: Ceglarek
authors.forename: Christof
authors.initials: C
authors.lastname: Lenz
authors.forename: Jérôme
authors.initials: J
authors.lastname: Vialaret
authors.forename: Alexander
authors.initials: A
authors.lastname: Scherl
authors.forename: Christophe
authors.initials: C
authors.lastname: Hirtz
mesh_terms: D015415:Biomarkers / Q000032:analysis; D002624:Chemistry, Clinical; D002853:Chromatography, Liquid; D006801:Humans; D010455:Peptides / Q000032:analysis*; D011506:Proteins / Q000032:analysis*; D040901:Proteomics; D053719:Tandem Mass Spectrometry
chemical_list: D015415:Biomarkers; D010455:Peptides; D011506:Proteins